ALC Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Sales: $2.8 billion, up 7% year-over-year.

Surgical Franchise: Sales of $1.6 billion, also up 7%. Implantables grew 1% to $466 million, with IOLs up 2%.

Vision Care: Sales of $1.2 billion, up 7%. Contact lenses grew 5% to $726 million, while ocular health sales rose 12% to $486 million.

Core Gross Margin: 64.7%, up 250 basis points year-over-year.

Core Operating Income: $574 million, representing 20.6% of sales, up 160 basis points.

Core Diluted EPS: $0.84, up 9% compared to the prior year.

Free Cash Flow: $693 million in the first half of the year, with $538 million returned to shareholders through dividends and buybacks.

2Strategic Updates and Business Highlights

Product Innovation: Strong demand for the UNITY VCS system, with ASPs exceeding expectations. The PanOptix Pro IOL family showed double-digit growth, capturing about 90% of PanOptix implants in the U.S.

New Product Launches: Upcoming launches include Vivity Pro and TruPlus, with CE Mark approval received for TruPlus in Europe.

Valeda for AMD: Adoption is accelerating, with potential sales projected between $100 million and $150 million over time.

Contact Lens Market: Achieved record global market share, particularly in the U.S., driven by products like TOTAL1 and PRECISION1.

3Forward Guidance and Outlook

2026 Sales Growth: Expected constant currency sales growth of 5% to 7%. The second half may face tougher comparisons in equipment but easier comparisons in contact lenses.

Profitability: Core operating margin expansion is anticipated to be between 90 to 190 basis points in constant currency.

Core Diluted EPS Growth: Increased outlook to 12% to 15% in constant currency, reflecting strong operational performance and share repurchase benefits.

4Bad News, Challenges, or Points of Concern

Discontinued Programs: The decision to halt the PowerVision IOL program due to unresolved clinical issues.

Competitive Pressures: The IOL market remains competitive, with challenges in maintaining share despite strong product performance.

U.S. Cataract Market: Flat growth in the U.S. market, attributed to a shortage of surgeons and capacity issues, which may limit future growth.

Equipment Comparisons: Anticipated tougher comparisons for equipment sales in the second half of the year.

5Notable Q&A Insights

UNITY Adoption: Strong visibility into UNITY order book, with a steady demand expected moving forward.

Tariff Refund Reinvestment: Plans to reinvest a portion of the $60 million tariff refund into marketing and sales efforts, particularly for new product launches.

TRYPTYR Performance: Positive trends noted in prescription demand and refill rates, indicating strong early adoption.

Market Dynamics: The U.S. contact lens market remains healthy, with price increases contributing to growth, while international markets face pricing challenges.

Future Product Pipeline: Confidence in upcoming product launches, including eye whitener and additional IOLs, is expected to drive growth beyond 2026. This summary encapsulates the key aspects of Alcon's Q2 2026 earnings call, highlighting both the positive developments and challenges faced by the company.